Engineering Extracellular Vesicles for Alzheimer's Disease: An Emerging Cell-free Approach for Earlier Diagnosis and Treatment

Overview

Journal WIREs Mech Dis

Specialties Biology
Biomedical Engineering
Genetics
Physiology

Date 2022 Mar 10

PMID 35266650

Authors

Sabrina Valentina Lazar

Sirjan Mor

David Wang

Leora Goldbloom-Helzner

Kaitlin Clark

Dake Hao

Diana Lee Farmer

Aijun Wang

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD) is a debilitating neurodegenerative disorder affecting over five million people globally and has no established cure. Current AD-related treatments only alleviate cognitive and behavioral symptoms and do not address disease onset or progression, underlining the unmet need to create an effective, innovative AD therapeutic. Extracellular vesicles (EVs) have emerged as a new class of nanotherapeutics. These secreted, lipid-bound cellular signaling carriers show promise for potential clinical applications for neurodegenerative diseases like AD. Additionally, analyzing contents and characteristics of patient-derived EVs may address the unmet need for earlier AD diagnostic techniques, informing physicians of altered genetic expression or cellular communications specific to healthy and diseased physiological states. There are numerous recent advances in regenerative medicine using EVs and include bioengineering perspectives to modify EVs, target glial cells in neurodegenerative diseases like AD, and potentially use EVs to diagnose and treat AD earlier. This article is categorized under: Neurological Diseases > Biomedical Engineering Neurological Diseases > Molecular and Cellular Physiology Neurological Diseases > Stem Cells and Development.

Citing Articles

Therapeutic role of extracellular vesicles from human umbilical cord mesenchymal stem cells and their wide therapeutic implications in inflammatory bowel disease and other inflammatory disorder.

Azhar Ud Din M, Wan A, Chu Y, Zhou J, Yan Y, Xu Z Front Med (Lausanne). 2024; 11:1406547.

PMID: 39139783 PMC: 11319305. DOI: 10.3389/fmed.2024.1406547.

Prospective applications of extracellular vesicle-based therapies in regenerative medicine: implications for the use of dental stem cell-derived extracellular vesicles.

Wang W, Xu Z, Liu M, Cai M, Liu X Front Bioeng Biotechnol. 2023; 11:1278124.

PMID: 37936823 PMC: 10627172. DOI: 10.3389/fbioe.2023.1278124.

New strategies of neurodegenerative disease treatment with extracellular vesicles (EVs) derived from mesenchymal stem cells (MSCs).

Palanisamy C, Pei J, Alugoju P, Anthikapalli N, Jayaraman S, Veeraraghavan V Theranostics. 2023; 13(12):4138-4165.

PMID: 37554286 PMC: 10405853. DOI: 10.7150/thno.83066.

Mitochondria-derived vesicles and their potential roles in kidney stone disease.

Chaiyarit S, Thongboonkerd V J Transl Med. 2023; 21(1):294.

PMID: 37131163 PMC: 10152607. DOI: 10.1186/s12967-023-04133-3.

Engineered extracellular vesicles with high collagen-binding affinity present superior retention and therapeutic efficacy in tissue repair.

Hao D, Lu L, Song H, Duan Y, Chen J, Carney R Theranostics. 2022; 12(13):6021-6037.

PMID: 35966577 PMC: 9373818. DOI: 10.7150/thno.70448.

References

Lopez O, Becker J, Chang Y, Klunk W, Mathis C, Price J . Amyloid deposition and brain structure as long-term predictors of MCI, dementia, and mortality. Neurology. 2018; 90(21):e1920-e1928. PMC: 5962915. DOI: 10.1212/WNL.0000000000005549. View

Matsumoto J, Stewart T, Banks W, Zhang J . The Transport Mechanism of Extracellular Vesicles at the Blood-Brain Barrier. Curr Pharm Des. 2017; 23(40):6206-6214. DOI: 10.2174/1381612823666170913164738. View

Liu P, Xie Y, Meng X, Kang J . History and progress of hypotheses and clinical trials for Alzheimer's disease. Signal Transduct Target Ther. 2019; 4:29. PMC: 6799833. DOI: 10.1038/s41392-019-0063-8. View

Hemonnot A, Hua J, Ulmann L, Hirbec H . Microglia in Alzheimer Disease: Well-Known Targets and New Opportunities. Front Aging Neurosci. 2019; 11:233. PMC: 6730262. DOI: 10.3389/fnagi.2019.00233. View

Lazaro-Ibanez E, Faruqu F, Saleh A, Silva A, Wang J, Rak J . Selection of Fluorescent, Bioluminescent, and Radioactive Tracers to Accurately Reflect Extracellular Vesicle Biodistribution . ACS Nano. 2021; 15(2):3212-3227. PMC: 7905875. DOI: 10.1021/acsnano.0c09873. View

Xian P, Hei Y, Wang R, Wang T, Yang J, Li J . Mesenchymal stem cell-derived exosomes as a nanotherapeutic agent for amelioration of inflammation-induced astrocyte alterations in mice. Theranostics. 2019; 9(20):5956-5975. PMC: 6735367. DOI: 10.7150/thno.33872. View

Qu M, Lin Q, Huang L, Fu Y, Wang L, He S . Dopamine-loaded blood exosomes targeted to brain for better treatment of Parkinson's disease. J Control Release. 2018; 287:156-166. DOI: 10.1016/j.jconrel.2018.08.035. View

Santa-Maria I, Alaniz M, Renwick N, Cela C, Fulga T, Van Vactor D . Dysregulation of microRNA-219 promotes neurodegeneration through post-transcriptional regulation of tau. J Clin Invest. 2015; 125(2):681-6. PMC: 4319412. DOI: 10.1172/JCI78421. View

Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland T . A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease. Cell. 2017; 169(7):1276-1290.e17. DOI: 10.1016/j.cell.2017.05.018. View

10.

Xin H, Li Y, Cui Y, Yang J, Zhang Z, Chopp M . Systemic administration of exosomes released from mesenchymal stromal cells promote functional recovery and neurovascular plasticity after stroke in rats. J Cereb Blood Flow Metab. 2013; 33(11):1711-5. PMC: 3824189. DOI: 10.1038/jcbfm.2013.152. View

11.

Molinaro R, Evangelopoulos M, Hoffman J, Corbo C, Taraballi F, Martinez J . Design and Development of Biomimetic Nanovesicles Using a Microfluidic Approach. Adv Mater. 2018; 30(15):e1702749. DOI: 10.1002/adma.201702749. View

12.

Aguzzi A, Barres B, Bennett M . Microglia: scapegoat, saboteur, or something else?. Science. 2013; 339(6116):156-61. PMC: 4431634. DOI: 10.1126/science.1227901. View

13.

Lin Y, Seo J, Gao F, Feldman H, Wen H, Penney J . APOE4 Causes Widespread Molecular and Cellular Alterations Associated with Alzheimer's Disease Phenotypes in Human iPSC-Derived Brain Cell Types. Neuron. 2018; 98(6):1141-1154.e7. PMC: 6023751. DOI: 10.1016/j.neuron.2018.05.008. View

14.

Crous-Bou M, Minguillon C, Gramunt N, Molinuevo J . Alzheimer's disease prevention: from risk factors to early intervention. Alzheimers Res Ther. 2017; 9(1):71. PMC: 5596480. DOI: 10.1186/s13195-017-0297-z. View

15.

Hosseini Shamili F, Bayegi H, Salmasi Z, Sadri K, Mahmoudi M, Kalantari M . Exosomes derived from TRAIL-engineered mesenchymal stem cells with effective anti-tumor activity in a mouse melanoma model. Int J Pharm. 2018; 549(1-2):218-229. DOI: 10.1016/j.ijpharm.2018.07.067. View

16.

Saadatpour L, Fadaee E, Fadaei S, Nassiri Mansour R, Mohammadi M, Mousavi S . Glioblastoma: exosome and microRNA as novel diagnosis biomarkers. Cancer Gene Ther. 2016; 23(12):415-418. DOI: 10.1038/cgt.2016.48. View

17.

Jovicic A, Gitler A . Distinct repertoires of microRNAs present in mouse astrocytes compared to astrocyte-secreted exosomes. PLoS One. 2017; 12(2):e0171418. PMC: 5289606. DOI: 10.1371/journal.pone.0171418. View

18.

Ren X, Zhao Y, Xue F, Zheng Y, Huang H, Wang W . Exosomal DNA Aptamer Targeting α-Synuclein Aggregates Reduced Neuropathological Deficits in a Mouse Parkinson's Disease Model. Mol Ther Nucleic Acids. 2019; 17:726-740. PMC: 6709346. DOI: 10.1016/j.omtn.2019.07.008. View

19.

Goetzl E, Mustapic M, Kapogiannis D, Eitan E, Lobach I, Goetzl L . Cargo proteins of plasma astrocyte-derived exosomes in Alzheimer's disease. FASEB J. 2016; 30(11):3853-3859. PMC: 5067254. DOI: 10.1096/fj.201600756R. View

20.

Liu Y, Huber C, Wang H . Disrupted blood-brain barrier in 5×FAD mouse model of Alzheimer's disease can be mimicked and repaired in vitro with neural stem cell-derived exosomes. Biochem Biophys Res Commun. 2020; . DOI: 10.1016/j.bbrc.2020.02.074. View